TargetRAF proto-oncogene serine/threonine-protein kinase(Homo sapiens (Human))
Genentech
Curated by ChEMBL
Genentech
Curated by ChEMBL
Affinity DataKi: <0.0500nMAssay Description:Inhibition of CRAF Y340D/Y341D mutant (unknown origin) assessed as using inactive phosphorylated MAP2K1 substrate preincubated for 30 mins measured a...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase(Homo sapiens (Human))
Genentech
Curated by ChEMBL
Genentech
Curated by ChEMBL
Affinity DataKi: <0.0500nMAssay Description:Inhibition of CRAF Y340D/Y341D mutant (unknown origin) using inactive MAP2K1 as substrate preincubated for 30 mins measured after 90 mins by DELFIA a...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase(Homo sapiens (Human))
Genentech
Curated by ChEMBL
Genentech
Curated by ChEMBL
Affinity DataKi: <0.0500nMAssay Description:Inhibition of CRAF Y340D/Y341D mutant (unknown origin) using inactive MAP2K1 as substrate preincubated for 30 mins measured after 90 mins by DELFIA a...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase(Homo sapiens (Human))
Genentech
Curated by ChEMBL
Genentech
Curated by ChEMBL
Affinity DataKi: <0.0500nMAssay Description:Inhibition of CRAF Y340D/Y341D mutant (unknown origin) using inactive MAP2K1 as substrate preincubated for 30 mins measured after 90 mins by DELFIA a...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase(Homo sapiens (Human))
Genentech
Curated by ChEMBL
Genentech
Curated by ChEMBL
Affinity DataKi: <0.0500nMAssay Description:Inhibition of CRAF Y340D/Y341D mutant (unknown origin) using inactive MAP2K1 as substrate preincubated for 30 mins measured after 90 mins by DELFIA a...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase(Homo sapiens (Human))
Genentech
Curated by ChEMBL
Genentech
Curated by ChEMBL
Affinity DataKi: <0.0500nMAssay Description:Inhibition of CRAF Y340D/Y341D mutant (unknown origin) assessed as using inactive phosphorylated MAP2K1 substrate preincubated for 30 mins measured a...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase(Homo sapiens (Human))
Genentech
Curated by ChEMBL
Genentech
Curated by ChEMBL
Affinity DataKi: <0.0500nMAssay Description:Inhibition of CRAF Y340D/Y341D mutant (unknown origin) assessed as using inactive phosphorylated MAP2K1 substrate preincubated for 30 mins measured a...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase(Homo sapiens (Human))
Genentech
Curated by ChEMBL
Genentech
Curated by ChEMBL
Affinity DataKi: 0.0600nMAssay Description:Inhibition of CRAF Y340D/Y341D mutant (unknown origin) using inactive MAP2K1 as substrate preincubated for 30 mins measured after 90 mins by DELFIA a...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase(Homo sapiens (Human))
Genentech
Curated by ChEMBL
Genentech
Curated by ChEMBL
Affinity DataKi: 0.0600nMAssay Description:Inhibition of CRAF Y340D/Y341D mutant (unknown origin) assessed as using inactive phosphorylated MAP2K1 substrate preincubated for 30 mins measured a...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase(Homo sapiens (Human))
Genentech
Curated by ChEMBL
Genentech
Curated by ChEMBL
Affinity DataKi: 0.0610nMAssay Description:Inhibition of CRAF Y340D/Y341D mutant (unknown origin) assessed as using inactive phosphorylated MAP2K1 substrate preincubated for 30 mins measured a...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase(Homo sapiens (Human))
Genentech
Curated by ChEMBL
Genentech
Curated by ChEMBL
Affinity DataKi: 0.0610nMAssay Description:Inhibition of CRAF Y340D/Y341D mutant (unknown origin) assessed as using inactive phosphorylated MAP2K1 substrate preincubated for 30 mins measured a...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase(Homo sapiens (Human))
Genentech
Curated by ChEMBL
Genentech
Curated by ChEMBL
Affinity DataKi: 0.0610nMAssay Description:Inhibition of CRAF Y340D/Y341D mutant (unknown origin) using inactive MAP2K1 as substrate preincubated for 30 mins measured after 90 mins by DELFIA a...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase(Homo sapiens (Human))
Genentech
Curated by ChEMBL
Genentech
Curated by ChEMBL
Affinity DataKi: 0.0610nMAssay Description:Inhibition of CRAF Y340D/Y341D mutant (unknown origin) using inactive MAP2K1 as substrate preincubated for 30 mins measured after 90 mins by DELFIA a...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase(Homo sapiens (Human))
Genentech
Curated by ChEMBL
Genentech
Curated by ChEMBL
Affinity DataKi: 0.0620nMAssay Description:Inhibition of CRAF Y340D/Y341D mutant (unknown origin) assessed as using inactive phosphorylated MAP2K1 substrate preincubated for 30 mins measured a...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase(Homo sapiens (Human))
Genentech
Curated by ChEMBL
Genentech
Curated by ChEMBL
Affinity DataKi: 0.0810nMAssay Description:Inhibition of CRAF Y340D/Y341D mutant (unknown origin) assessed as using inactive phosphorylated MAP2K1 substrate preincubated for 30 mins measured a...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase(Homo sapiens (Human))
Genentech
Curated by ChEMBL
Genentech
Curated by ChEMBL
TargetRAF proto-oncogene serine/threonine-protein kinase(Homo sapiens (Human))
Genentech
Curated by ChEMBL
Genentech
Curated by ChEMBL
TargetRAF proto-oncogene serine/threonine-protein kinase(Homo sapiens (Human))
Genentech
Curated by ChEMBL
Genentech
Curated by ChEMBL
TargetRAF proto-oncogene serine/threonine-protein kinase(Homo sapiens (Human))
Genentech
Curated by ChEMBL
Genentech
Curated by ChEMBL
TargetRAF proto-oncogene serine/threonine-protein kinase(Homo sapiens (Human))
Genentech
Curated by ChEMBL
Genentech
Curated by ChEMBL
Affinity DataKi: >1.00E+3nMAssay Description:Inhibition of c-Raf (unknown origin)More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase(Homo sapiens (Human))
Genentech
Curated by ChEMBL
Genentech
Curated by ChEMBL
Affinity DataKi: >2.00E+3nMAssay Description:Inhibition of C-RAFMore data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase(Homo sapiens (Human))
Genentech
Curated by ChEMBL
Genentech
Curated by ChEMBL
Affinity DataKi: >1.00E+4nMAssay Description:Inhibition of RAFc (unknown origin)More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase(Homo sapiens (Human))
Genentech
Curated by ChEMBL
Genentech
Curated by ChEMBL
Affinity DataKi: >1.00E+4nMAssay Description:Inhibition of RAFc (unknown origin)More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 0.00100nMAssay Description:The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: <0.00200nMAssay Description:The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 0.00200nMAssay Description:The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 0.00200nMAssay Description:The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: <0.00200nMAssay Description:The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 0.00200nMAssay Description:The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: <0.00200nMAssay Description:The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 0.00300nMAssay Description:The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 0.00400nMAssay Description:The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 0.00500nMAssay Description:The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 0.00500nMAssay Description:The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 0.00500nMAssay Description:The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 0.00500nMAssay Description:The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 0.00500nMAssay Description:The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 0.00500nMAssay Description:The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 0.00500nMAssay Description:The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 0.00600nMAssay Description:The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 0.00600nMAssay Description:The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 0.00600nMAssay Description:The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 0.00600nMAssay Description:The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 0.00700nMAssay Description:The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 0.00700nMAssay Description:The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 0.00800nMAssay Description:The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 0.00800nMAssay Description:The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 0.00800nMAssay Description:The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 0.00800nMAssay Description:The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
Novartis
US Patent
Novartis
US Patent
Affinity DataIC50: 0.00900nMAssay Description:The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...More data for this Ligand-Target Pair